|
Post by gonetotown on Sept 28, 2016 20:36:00 GMT -5
It's interesting but has to many shortcomings for me: It works by continually altering the basal to hold you in range and cannot do a single shot bolus if you are high. It's average target is higher than I would like and I cannot see a way to tune that. I still have to manually bolus for meals (using the pump) It is insulin only, I want a dual hormone AP. And it's made by Medtronics which means it will be clunky and vaguely dated (prejudiced? Me?) More seriously there are going to be a lot of APs out next year and for the most part they look like they will be better. If I get the 670G it's 4 years before I can get another pump from my current insurer. I doubt there will be any problems with insurance companies since except for UHC they all let you pick the pump you want. Is it correct that UHC reimburses the cost Medtronic device?
|
|
|
Post by agedhippie on Sept 28, 2016 20:44:30 GMT -5
Now AFREZZA: 1. AFREZZA is getting PWD as low as 4.8 and generally within mid 5's to low 6's for those that learn how to titrate properly. (His is a 6.2 although may be better since article) 2. No carb counting 3. As Gus B and many others say, they live like they don't have diabetes anymore... (He is still thinking about it all day) There are more comparisons to be made but for not I think I have made my point... Very disturbing that such a great drug is virtually ignored and a new piece of technology that is admittedly imperfect is getting such attention and phase... Getting your HbA1c below 6.5 really doesn't get you anything. That doesn't stop people from doing it though but really it's mostly for bragging rights (see the Dr Bernstein crowd as an example). You still have to carb count with Afrezza, the benefit is that you don't have to carb count that precisely (carb estimate?). One thing that was interesting in the trial data was the hypo results - a 44% reduction of hypos and 40% reduction of severe hypos, that's better than the Afrezza trial data. I would speculate that it achieves that by taking a high average although the range control still ensures a good HbA1c. The 670G is interesting but more as a precursor of what is to come than as a usable AP. There is a development line here - last year you had the 630G which would suspend basal when it thinks you are going low, this year you have the 670G that will dynamically modify that basal to keep you in range. Where next? Hopefully a full AP.
|
|
|
Post by agedhippie on Sept 28, 2016 20:45:49 GMT -5
It's interesting but has to many shortcomings for me: It works by continually altering the basal to hold you in range and cannot do a single shot bolus if you are high. It's average target is higher than I would like and I cannot see a way to tune that. I still have to manually bolus for meals (using the pump) It is insulin only, I want a dual hormone AP. And it's made by Medtronics which means it will be clunky and vaguely dated (prejudiced? Me?) More seriously there are going to be a lot of APs out next year and for the most part they look like they will be better. If I get the 670G it's 4 years before I can get another pump from my current insurer. I doubt there will be any problems with insurance companies since except for UHC they all let you pick the pump you want. Is it correct that UHC reimburses the cost Medtronic device? Yes, and only Medtronics. There is a campaign going on at the moment to get that changed before it spreads and other insurers do the same.
|
|
|
Post by sweedee79 on Sept 28, 2016 21:55:21 GMT -5
If you believe the JDRF it should actually increase afrezza use. afrezza was the best way they controlled meal time spikes at about the 2:50m and 4:30m mark. youtube.com/watch?v=GGgGjtM5ipg Now the bigger problem is afrezza works so well why do you need the AP at all if a shot of Tresiba and afrezza work as well. I would rather have Afrezza... its a healthier insulin... I'm convinced.. what kind of insulin will the AP use???
|
|
|
Post by agedhippie on Sept 28, 2016 21:59:19 GMT -5
If you believe the JDRF it should actually increase afrezza use. afrezza was the best way they controlled meal time spikes at about the 2:50m and 4:30m mark. youtube.com/watch?v=GGgGjtM5ipg Now the bigger problem is afrezza works so well why do you need the AP at all if a shot of Tresiba and afrezza work as well. I would rather have Afrezza... its a healthier insulin... I'm convinced.. what kind of insulin will the AP use??? The usual suspects - Novolog/Humalog/Apidra
|
|
|
Post by sweedee79 on Sept 28, 2016 22:02:56 GMT -5
I would rather have Afrezza... its a healthier insulin... I'm convinced.. what kind of insulin will the AP use??? The usual suspects - Novolog/Humalog/Apidra I suppose Apidra wouldn't be so bad, I don't know much about it other than its faster.. but insurance companies don't seem to want to cover that either....
|
|
|
Post by dictatorsaurus on Sept 28, 2016 22:12:45 GMT -5
At 300 scripts per week, how much more can the AP take away from Afrezza? Drop us back down to 200?
Reading from the trial participant it seems far from perfect and lots of work. It's interesting he loved Exubera. If he loved that bong imagine how much more he would be into the whistle.
|
|
|
Post by agedhippie on Sept 29, 2016 6:18:55 GMT -5
At 300 scripts per week, how much more can the AP take away from Afrezza? Drop us back down to 200? Reading from the trial participant it seems far from perfect and lots of work. It's interesting he loved Exubera. If he loved that bong imagine how much more he would be into the whistle. I don't see this as a serious threat. The 670G is not launched until next year and it's not going to sell that many. People will hold off for the dual chambered pumps that are coming next year.
|
|
|
Post by mnholdem on Sept 29, 2016 7:39:07 GMT -5
On a related note, you may find this interesting:
Medallion Therapeutics, Inc., another AMF company founded by Alfred E Mann, recently completed trials of "an innovative infusion pump which will provide totally accurate delivery of prescribed drugs to people suffering from chronic illnesses such as diabetes and neurodegenerative diseases."
"According to a spokesperson from Medallion Therapeutics the development of the infusion pump by the team at AMF comes after more than 10 years of research and development to create the novel Medallion implantable drug delivery system.
"Announcing the formation of Medallion Therapeutics David Hankin, Chief Executive Officer of the Alfred Mann Foundation, remarked that the new infusion pump holds considerable promise of providing patients and physicians with a superior method of infusion therapy than what is currently available on the market."
Source: jewishbusinessnews.com/2014/03/06/the-alfred-mann-foundation-launches-medallion-therapeutics/
---
I contacted Medallion Therapeutics earlier this week, as I have been following the FDA trial for this pump for the past two years:
ClinicalTrials.gov Identifier: NCT01185470 The Clinical Evaluation of Implantable Pump System For Safety And Delivery Accuracy In Patients Requiring Intrathecal Administration Of Morphine Sulfate For Chronic Pain clinicaltrials.gov/ct2/show/record/NCT01185470?term=medallion+therapeutics&rank=1
I asked if the trial was completed (was to be completed in June) and I received a reply from John Petrovich, AMF Senior Vice President Business Development and General Counsel. John is now CEO of Medallion, having replaced former CEO Don Deyo and John's reply was as follows:
"In response to your question, the clinical trial concluded successfully, meeting all end points, and is now in a followup phase, hence no update to the clinicaltrials.gov info, the trial is no longer actively recruiting patients, and it is not typical to post results on that website. We are currently before the FDA with our PMA application, and hope to have resolution of that sometime next year."
---
According to the original article (above) the clinical evaluation for the pump in the United States would "clear the path for an upcoming submission for pre-market approval (PMA), while at the same time as pursuing CE Mark certification to support distribution in Europe."
Once again, the legendary Alfred E. Mann simply amazes me with the creation of a implantable device that would significantly lower the amount of medication currently needed for pain management while increasing its effectiveness. The pump has broader implications which I won't get into here but, IMHO, Mann was truly a visionary way ahead of his time.
|
|
|
Post by careful2invest on Sept 29, 2016 7:50:53 GMT -5
Medallion Therapeutics, Inc., another AMF company founded by Alfred E Mann, recently completed trials of "an innovative infusion pump which will provide totally accurate delivery of prescribed drugs to people suffering from chronic illnesses such as diabetes and neurodegenerative diseases."
"According to a spokesperson from Medallion Therapeutics the development of the infusion pump by the team at AMF comes after more than 10 years of research and development to create the novel Medallion implantable drug delivery system.
"Announcing the formation of Medallion Therapeutics David Hankin, Chief Executive Officer of the Alfred Mann Foundation, remarked that the new infusion pump holds considerable promise of providing patients and physicians with a superior method of infusion therapy than what is currently available on the market
I do find that interesting! I also found it interesting that the "artificial pancreas" gets a relatively fast approval by he FDA, and while watching ABC news this morning, they announce the pump, show photos of it, etc. The very next day after approval, major media exposure!
The contrast of the path that AFREZZA has had to take has been very different, to say the least. Just an observation... GLTA TRUE LONGS!
|
|
|
Post by sportsrancho on Sept 30, 2016 4:53:44 GMT -5
|
|
|
Post by kc on Jul 20, 2020 20:27:03 GMT -5
This was the pet project of Alejandro Galindo! We are very pleased to offer this added flexibility for those who rely on our therapies for their diabetes management needs,” Alejandro Galindo, president of Medtronic's Intensive Insulin Management division, said in a statement. You just have to wonder if medtronic is looking to add a new device to the diabetes arsenal 😉
|
|
|
Post by kc on Jul 20, 2020 20:31:50 GMT -5
|
|
|
Post by kc on Jul 20, 2020 20:59:46 GMT -5
|
|
|
Post by rockstarrick on Jul 24, 2020 2:16:37 GMT -5
My opinion/understanding is the following: 1. It will be expensive 2. Still rather bulky and inconvenient 3. Results still not that much better than a CGM, AFREZZA and a basil, (yes I know this depends on how diligent one is) 4. If T1's are looking to drop pump (and many are able to do so with an Hba1c in the mid 5's to low 6's) why get hooked to an AP? 5. More moving parts and chances for something to go wrong. I have a friend whose son almost died because his pump was not calibrated properly 6. Oh yeah... didn't the Samsun trials in Santa Barbara for an AP use AFREZZA? Can't get a Dexcom approved very easily how will insurance look at an AP? Just my initial thoughts... AFREZZA is simpler, less expensive, almost as able to get same results, and likely to some degree more convenient... But I am not diabetic so would love to hear from someone who is... www.jdrf.org/illinois/wp-content/uploads/sites/83/2013/07/The-Artificial-Pancreas-A-Race-to-the-Finish.pdf😎
|
|